- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Retifanlimab, Chemotherapy, 9-ING-41
- Drug
- Lead sponsor
- Anwaar Saeed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 290
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- PTSD
- Interventions
- Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Written Exposure Therapy
- Drug · Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 15
- States / cities
- North Little Rock, Arkansas • West Memphis, Arkansas • San Diego, California + 11 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Bitopertin, Placebo, SSRI
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 27
- States / cities
- Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
- Conditions
- Depressive Disorder
- Interventions
- Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care
- Behavioral · Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- SX-682, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 6
- States / cities
- Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
- Conditions
- Major Depressive Disorder
- Interventions
- Cognitive Behavioral Therapy (CBT), Escitalopram
- Behavioral · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Knee Osteoarthritis, Depression
- Interventions
- Aerobic exercise, Duloxetine
- Behavioral · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Open Angle Glaucoma or Ocular Hypertension
- Interventions
- Netarsudil ophthalmic solution 0.02%, Artificial tears
- Drug
- Lead sponsor
- East Coast Institute for Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Bladder Cancer
- Interventions
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin
- Drug · Radiation · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more
- Conditions
- Locally Advanced Rectal Cancer (LARC)
- Interventions
- NG-350A IV administration, Capecitabine oral administration, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Akamis Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orlando, Florida • St Louis, Missouri + 2 more
- Conditions
- Major Depressive Disorder
- Interventions
- Escitalopram, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Selinexor (KPT-330)
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Tampa, Florida • Evanston, Illinois + 11 more
- Conditions
- Breast Neoplasms
- Interventions
- Chemotherapy
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Vincennes, Indiana • Arlington, Texas + 1 more
- Conditions
- Urgency Urinary Incontinence
- Interventions
- Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, PET, INRT, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
- Drug · Diagnostic Test · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Stanford, California • Reading, Pennsylvania
- Conditions
- Liver Diseases, Portal Hypertension
- Interventions
- SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 3 more
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Brief Pain Inventory, Hospital Anxiety and Depression Scale, Neuropathic Pain Symptom Inventory, Diode Laser fiber type Selective Stimulator, Quantitative sensory testing, Conditioned pain modulation efficiency, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)
- Other · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- Interventions
- GC4419
- Drug
- Lead sponsor
- Galera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 10
- States / cities
- Lakeland, Florida • Iowa City, Iowa • St Louis, Missouri + 7 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Addario Lung Cancer Medical Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- San Carlos, California
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more
- Conditions
- Chronic Lymphocytic Leukemia, Richter's Transformation
- Interventions
- Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
- Drug
- Lead sponsor
- Christine Ryan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
- Conditions
- Depression, Amyotrophic Lateral Sclerosis
- Interventions
- Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI")
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Central Nervous System Tumors, Glioma
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more